Dr. Yao is CEO and Chairman of ArriVent Biopharma and has over 25 years of experience in the biotechnology and pharmaceuticals industry. He co-founded Viela Bio in 2018, serving as Chairman and CEO, which was acquired by Horizon Therapeutics for $3 billion in 2021. Prior to Viela, he held leadership positions at MedImmune and AstraZeneca, playing key roles in the development of multiple novel biologics. He has authored 50+ publications and holds 20+ patents and patent applications.